Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients

Journal of Investigative Medicine

Volumn 57, Issue 3, 2009, Pages 495-499

  Sukhija, Rishi ^a   Prayaga, Sastry ^a   Marashdeh, Mohammad ^a   Bursac, Zoran ^a   Kakar, Priyanka ^b   Bansal, Darpan ^a   Sachdeva, Rajesh ^a   Kesan, Sree Hari ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FORT SMITH   (United States)

Author keywords

Diabetes mellitus; Dyslipidemia; Hypertension; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DIET RESTRICTION; DRUG UTILIZATION; FASTING BLOOD GLUCOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; SIDE EFFECT; VETERAN;

AGED; BLOOD GLUCOSE; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; FASTING; FOOD DEPRIVATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 67650702822     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318197ec8b     Document Type: Article

References (18)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.
4. Collins R, Armitage J, Parish S, et al. MRC/BHJ Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361: 2005-2016.
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004; 9435:685-696.
6. Sabatine MS, Wiviott SD, Morrow DA, et al. High dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 Sub study. Circulation. 2004;110(Suppl I):S834.
7. 2+ channels in rat islet B cells. Br J Pharmacol. 1999;126:1205-1213.
8. Nakata M, Nagasaka S, Kusaka I, et al. Effect of statins on the adipocyte maturation and exoression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia. 2006;49:1881-1892.
9. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103:357-362.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
11. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scadinavian Cardiac Outcomes Trail. Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149-1158.
12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
13. Nielson C, Lange T, Hadjokas N. Blood glucose and coronary artery disease in nondiabetic patients. Diabetes Care. 2006;29:998-1001.
14. Santaguida PL, Balion C, Hunt D, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence report/technology assessment No. 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Pub. No 05-E026-2. Rockville, MD: Agency for Healthcare Research and Quality;2005.
15. Levitan EB, Song Y, Ford ES, et al. Is non-diabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 164:2147-2155.
16. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001;507: 357-361.
17. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005;12:111-119.
18. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006;13(3):123-129.